Statute Details
- Title: Medicines (Labelling of Chinese Proprietary Medicines) Regulations
- Act Code: MA1975-RG13
- Legislation Type: Subsidiary legislation (SL)
- Current status: Current version as at 27 Mar 2026
- Authorising Act: Medicines Act (Chapter 176), in particular sections 44, 45, 46 and 52
- Citation: G.N. No. S 494/1998 (Revised Edition 2005)
- Commencement: 1 Sep 1999 (as per the revised edition timeline shown)
- Key provisions (from extract): Regulation 2 (definitions), Regulation 2A (scope/exclusion), Regulation 3 (particulars on container/package/leaflet), Regulation 5 (certain substances to be labelled), Regulation 6 (prohibition of certain labels/leaflets)
- Schedule: Substances to be labelled (with English declaration requirements)
- Notable amendments shown in timeline: S 315/2005, S 557/2002, S 546/2016 (effective 1 Nov 2016, including insertion of Regulation 2A)
What Is This Legislation About?
The Medicines (Labelling of Chinese Proprietary Medicines) Regulations (“the Regulations”) set out Singapore’s mandatory labelling requirements for Chinese proprietary medicines. In practical terms, the Regulations require manufacturers, wholesalers, importers, and sellers to ensure that products are presented to consumers with specified information on the container, any outer package, and any leaflet that accompanies the medicine.
The policy goal is consumer protection and market integrity. Chinese proprietary medicines are a category of traditional medicines regulated under Singapore’s broader medicines framework. Because these products may be sold directly to the public, the Regulations aim to ensure that consumers receive accurate, non-misleading information—particularly about identity, ingredients, dosage, intended use, and safety-related warnings (including possible side effects and contraindications).
The Regulations also address regulatory risk from misleading therapeutic claims. They prohibit certain types of statements on labels and leaflets—specifically claims that a product will prevent, alleviate, or cure diseases or conditions listed in the First Schedule to the Medicines Act. In addition, the Regulations require specific English declarations when certain substances are present in the product, reflecting a targeted approach to substances that may raise safety or compliance concerns.
What Are the Key Provisions?
1. Definitions and interpretive framework (Regulation 2)
The Regulations define key terms that drive compliance. Two definitions are particularly important for labelling content:
- “Appropriate non-proprietary name” for the medicine and ingredients: this is tied to approved reference works (such as “A Dictionary of Chinese Pharmacy” (中药大辞典) and “The Chinese Herbal Medicine Materia Medica” (本草纲目)) or other names descriptive of the true nature of the medicine/ingredient, subject to Ministerial approval.
- “Appropriate quantitative particulars”: this requires ingredient quantities expressed in weight/volume/capacity/units of activity, or (where there is no dosage unit) the quantity of active ingredients by weight/volume/percentage by weight or volume of the total quantity.
These definitions matter because they determine the level of specificity expected on labels. A “brand name” alone is not enough; the Regulations require non-proprietary naming and quantitative ingredient disclosure (subject to limited exceptions).
2. Scope and exclusion for clinical research materials (Regulation 2A)
Regulation 2A provides that the Regulations do not apply to any Chinese proprietary medicine that is “clinical research material” as defined under the Medicines (Medicinal Products as Clinical Research Materials) Regulations 2016. This is a significant compliance carve-out: clinical research products are governed by a separate regulatory regime, and labelling obligations may differ accordingly.
3. Mandatory particulars on container, package, and leaflet (Regulation 3)
Regulation 3 is the core compliance provision. It prohibits sale or supply unless specified particulars are stated in the required places:
- Container labelling: must include specified particulars.
- Outer package labelling (where the container is immediately enclosed in a package): must include additional specified particulars.
- Leaflet content (where a leaflet is supplied): must include further required particulars.
The Regulations list the particulars in Regulation 3(2). From the extract, the required items include:
- Trade/brand name under which the medicine is sold.
- Appropriate non-proprietary name of the medicine.
- Batch reference given by the manufacturer.
- Expiry or “date after which” it should not be used.
- Wholesaler or importer details (name and address; importer details apply if imported).
- Manufacturer details (name and address, including country of manufacture).
- Assembler details (name and address) if applicable.
- Non-proprietary names of ingredients.
- Quantitative particulars of ingredients.
- Recommended dosage.
- Purpose(s) for which it is to be used.
- Purpose(s) for which it should not be used.
- Possible side effects.
- Directions for use, including time and method of administration.
Exceptions for ingredient names/quantities (Regulation 3(3))
Regulation 3(3) provides a limited exception: the particulars relating to ingredient non-proprietary names and quantitative particulars may be omitted if the formula is certified by the relevant health authority of the country of manufacture as a “secret or protected formula”, or if the Minister is satisfied that the formula is secret or protected where the manufacturing country does not certify such formulae. This is a narrow intellectual-property protection mechanism, but it is not automatic; it requires certification or Ministerial satisfaction.
Practical labelling constraints (Regulation 3(4)–(6))
The Regulations also address real-world packaging limitations:
- If the container is too small to reasonably state all ingredient particulars, precedence is given according to the order in Regulation 3(2), and omitted particulars must be stated on the outer package.
- If sold without a package, certain particulars (notably wholesaler/importer, manufacturer, and assembler details) must be stated on the container.
- If sold without a leaflet, certain usage and safety particulars (dosage, purposes, side effects, and directions) must be stated on the container or package in any order.
4. Labelling of certain substances (Regulation 5 and the Schedule)
Regulation 5 imposes a targeted labelling requirement for products containing substances listed in the Schedule. If a Chinese proprietary medicine contains any Schedule substance, it may not be sold or supplied unless the container (and any immediate outer package) is labelled with an English statement declaring the presence of that substance. The statement may use a corresponding term specified in the Schedule or any equivalent term.
This provision is important for compliance because it creates a clear, substance-specific obligation. Even if the general labelling requirements under Regulation 3 are satisfied, failure to include the required English declaration for Schedule substances can still render the product non-compliant.
5. Prohibition of certain labels and leaflets (Regulation 6)
Regulation 6 is a key enforcement lever against misleading therapeutic claims. It provides:
- No person shall sell or supply a Chinese proprietary medicine if the container or package contains any statement or representation that claims, indicates, or suggests the medicine will prevent, alleviate, or cure any disease or condition specified in the First Schedule to the Medicines Act.
- No person shall supply (or possess for supply) any leaflet containing similar prohibited statements or representations.
In other words, the Regulations restrict therapeutic claims tied to diseases/conditions enumerated in the Medicines Act framework. For practitioners, this means that label copy review must be done not only for accuracy but also for categorical compliance with the First Schedule list. A claim that is arguably “traditional” or “supportive” may still be captured if it suggests prevention/alleviation/cure of a listed disease/condition.
How Is This Legislation Structured?
The Regulations are structured as follows:
- Regulation 1: Citation.
- Regulation 2: Definitions (including “appropriate non-proprietary name” and “appropriate quantitative particulars”).
- Regulation 2A: Scope exclusion for clinical research materials.
- Regulation 3: Core labelling requirements—particulars to be shown on container, package, and leaflet, including detailed lists and practical rules for small containers and leaflet-less sales.
- Regulation 4: Deleted (as shown in the timeline).
- Regulation 5: Labelling of certain substances—requires English declarations for Schedule substances.
- Regulation 6: Prohibition of certain labels and leaflets—restricts therapeutic claims relating to diseases/conditions in the First Schedule to the Medicines Act.
- Regulations 7–9: Additional rules on manner and language of particulars, and additional information to be shown (not fully reproduced in the extract, but indicated by the table of contents).
- The Schedule: Substances to be labelled (with corresponding English terms).
Who Does This Legislation Apply To?
The Regulations apply to “any person” who sells or supplies Chinese proprietary medicines in Singapore. In practice, this includes manufacturers, wholesalers, importers, and retailers, because the labelling obligations are framed around the act of sale or supply and require information about manufacturing, wholesaling, and importing.
The Regulations also impose obligations that extend to leaflet supply and possession for supply (Regulation 6(2)). Therefore, compliance is not limited to packaging design; it also covers marketing materials and informational leaflets that accompany the medicine.
Why Is This Legislation Important?
For practitioners, the Regulations are important because they create clear, documentable labelling duties that can be assessed by inspection and enforcement. Unlike broad “general safety” standards, these Regulations specify exact categories of information and impose categorical prohibitions on certain therapeutic claims.
From a compliance and risk perspective, Regulation 3 drives the “minimum content” standard for labels and leaflets. Regulation 5 adds a second layer—substance-specific English declarations—while Regulation 6 addresses the most sensitive area: disease/condition claims linked to the First Schedule to the Medicines Act. Together, these provisions mean that a product can be non-compliant even if it is otherwise accurately described, simply because it contains a prohibited claim or omits a required Schedule substance declaration.
Finally, Regulation 2A’s exclusion for clinical research materials underscores that the labelling regime is not one-size-fits-all. If a product is being used in clinical research, it may fall under a different regulatory framework, and counsel should ensure the correct classification before advising on labelling obligations.
Related Legislation
- Medicines Act (Chapter 176), including the First Schedule to the Act (referenced by Regulation 6) and sections 44, 45, 46 and 52 (authorising provisions).
- Medicines (Medicinal Products as Clinical Research Materials) Regulations 2016 (G.N. No. S 336/2016), referenced for the definition of clinical research material in Regulation 2A.
- Medicines (Traditional Medicines, Homoeopathic Medicines and other Substances) (Exemption) Order (O 6), referenced for the definition of “Chinese proprietary medicine”.
Source Documents
This article provides an overview of the Medicines (Labelling of Chinese Proprietary Medicines) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.